![]() Prior to Oncovalent, he held roles of increasing responsibility at Amgen, including research project team leader for Lumakras. Formerly, Cee served as VP of chemistry for Oncovalent Therapeutics. Among her accomplishments at Amgen, Arvedson initiated its KRAS G12C-targeting effort, which resulted in the first approved KRAS-targeting molecule, Lumakras (sotorasib).Īnother Amgen veteran, Victor Cee, also joined Hexagon as SVP of drug discovery. She follows former CSO Tod Smeal, who joined as SCO in 2020, and is now serving as CSO at Cardiff Oncology.Īrvedson joined last year from Amgen, where she served as executive director of oncology research and led small- and large-molecule programs in oncology, immuno-oncology, inflammation and hematology. The company, whose initial programs are focused on oncology and infectious disease, said it plans to use proceeds to continue to grow its team across multiple disciplines as it expands the reach and capabilities of its platform.Īs for the most recent appointments, Tara Arvedson was promoted from SVP of research to chief scientific officer. ![]() The Series B round followed raises of $61 million in 2021, led by Nextech Invest, and a $47 million series A round in 2020, led by The Column Group.
0 Comments
Leave a Reply. |